Prolotherapy Injection: Difference between revisions

From WikiMSK

mNo edit summary
mNo edit summary
Line 1: Line 1:
{{stub}}
{{stub}}
{{nonmainstream}}
{{nonmainstream}}
See Hauser et al for a free open access systematic review from 2016. <ref>{{#pmid:27429562}}</ref>
See Hauser et al for a free open access systematic review from 2016.<ref>{{#pmid:27429562}}</ref>The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
The most commonly use agent is dextrose. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.
 
== Articles ==
[[Media:Fullerton2018.pdf]]


==References==
==References==

Revision as of 07:39, 7 March 2022

This article is a stub.
This page or section deals with a topic that is not widely recognised or accepted.
Please use your clinical judgement and note that this is not necessarily standard practice in NZ.

See Hauser et al for a free open access systematic review from 2016.[1]The most commonly use agent is dextrose usually in concentrations between 5-20%. Some use tetradecyl (2mL 3% tetradecyl diluted in 50mL vial of prilocaine to make 0.11%) or polidocanol for those with sulfate allergies. Dextrose can be obtained by MPSO, while tetradecyl and polidocanol can be obtained from NZ scientific and medical.

Articles

Media:Fullerton2018.pdf

References

  1. Hauser et al.. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clinical medicine insights. Arthritis and musculoskeletal disorders 2016. 9:139-59. PMID: 27429562. DOI. Full Text.

Literature Review